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Abstract: Charcot–Marie–Tooth (CMT) disease is the most common inherited neuropathy
and one of the most common inherited diseases in humans. The diagnosis of CMT is traditionally made by the neurologic specialist, yet the optimal management of CMT patients includes
genetic counselors, physical and occupational therapists, physiatrists, orthotists, mental health
providers, and community resources. Rapidly developing genetic discoveries and novel gene
discovery techniques continue to add a growing number of genetic subtypes of CMT. The first
large clinical natural history and therapeutic trials have added to our knowledge of each CMT
subtype and revealed how CMT impacts patient quality of life. In this review, we discuss several
important trends in CMT research factors that will require a collaborative multidisciplinary
approach. These include the development of large multicenter patient registries, standardized
clinical instruments to assess disease progression and disability, and increasing recognition and
use of patient-reported outcome measures. These developments will continue to guide strategies
in long-term multidisciplinary efforts to maintain quality of life and preserve functionality in
CMT patients.
Keywords: rehabilitation, genetic diagnosis, patient quality of life, inherited neuropathies,
hereditary motor and sensory neuropathies, longitudinal care

Introduction
Charcot–Marie–Tooth (CMT) disease is the most common inherited neuropathy, and
with an estimated prevalence of one in 2,500, one of the most common inherited
diseases in humans. CMT is a disorder that most commonly causes progressive distal to proximal weakness and associated atrophy as well as sensory deficits, usually
affecting the feet and legs at onset. It progresses in a length-dependent fashion eventually affecting the hands, but its clinical phenotype can range from mild functional
limitations to severe complicated diseases. It is broadly classified as demyelinating or
an axonal form, though intermediate forms exist, each with specific histopathologic,
electrodiagnostic, and genetic features. While neurologic examination, electrodiagnostic techniques, and genetic testing yield diagnostic and prognostic information, a
multidisciplinary supportive care team is critical to improve the quality of life (QoL)
in patients for this still incurable disease.
Correspondence: Nicholas E Johnson
Department of Neurology, Eccles
Institute of Human Genetics, University
of Utah, 15N 2030 E 2270A Salt Lake
City, UT 84112, USA
Tel +1 801 585 7575
Email nicholas.johnson@hsc.utah.edu

Classification, epidemiology, and genetics
CMT classically refers to inherited motor and sensory neuropathies with a wide
range of genotypes and phenotypes. Classification of the various types of CMT was
originally described by Dyck et al in 1975 and employed the term “hereditary motor
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and sensory neuropathy types I–VII”, also referred to CMT
types 1–7.1,2 These distinctions rely on electrodiagnostic
findings of either nerve conduction slowing, representing
demyelinating disease, or decreased compound muscle
action potential (CMAP) amplitudes, representing axonal
injury, as well as the presence of other clinical features.
This classification system described other hereditary
sensory and sensory-autonomic neuropathies, but did
not include other primary inherited neuropathies such as
hereditary neuropathy with pressure palsy and giant axonal
neuropathy.
While this classification system has provided a useful
basis to better understand clinical, pathological, and electrodiagnostic phenotype variability, identification of genetic
etiologies has furthered our understanding of the pathogenesis of CMT and allowed for further clinical refinement. The
most commonly encountered forms of CMT are generally
classified as type 1 (demyelinating) and type 2 (axonal).
Occasional cases share features of both axonal and demyelinating forms with intermediate conduction velocities,
and have been recently reviewed by Nicholson and Myers.3
For each CMT subtype, the known genetic classification is
denoted as a letter to identify the genetic etiology. An overview of single gene causes of CMT based on inheritance
patterns, pathology, and genetics had been simplified and
described by Bird and is summarized in Table 1.4 It should be
noted that there are rare allelic and complex CMT disorders;
for instance, mutations in MFN2 that cause CMT2A and rare
forms such as CMT6.5,6
The prevalence of CMT has been estimated as one in
2,500, but depending on geographic populations studied,
this estimate has ranged from one in ∼1,200 to 9,200.7–10
With respect to the subtypes of CMT, CMT type 1 is
thought most common, representing approximately half
to 80% of all CMT.11–14 In certain populations (Japan) or
when sporadic cases are included, a higher prevalence of
CMT2 is observed. Intermediate forms, which share features of types 1 and 2, consistently make up ,4% of cases.
In CMT type 1, PMP22 duplication (CMT1A) make up
the vast majority, with North American studies in clinical
populations consistently showing that PMP22 duplication
and point mutations account for ∼50% or more of CMT1;
international studies are variable and report ranges from
13% to 67%. The remaining genes known to cause CMT1
(LITAF, EGR2, and NEFL) likely account for ∼10% or less
of CMT1. In CMT type 2, mutations in MFN2 (CMT2A)
are thought to account for 15%–20% of CMT2 in clinical
studies, with other CMT2 genes (Rab7, TRPV4, GARS,
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NEFL, HSPB1, GDAP, HSPB8) accounting for a very small
minority of cases.6,15–17

Clinical diagnosis
The classic CMT patient will usually present with complaints
of lower extremity weakness, foot drop, and foot deformity
which is familial. Examination reveals sensory deficits and
motor weakness distally with associated muscular atrophy
and absent deep tendon reflexes. If there is a family history
of similar symptoms or diagnosis of neuropathy, CMT is a
likely diagnosis if no other neurologic signs or symptoms
are revealed. In cases without a clear family history, other
neurologic diagnosis within the family should be explored,
as family members may have been incorrectly diagnosed.
In both sporadic and hereditary cases, reversible causes of
neuropathy should be ruled out, and nerve conduction studies
should be performed to confirm the diagnosis, distinguish
from other neurologic entities, and further classify the CMT
type. In rare cases, CMT may present with other neurologic
symptoms, such as optic atrophy, ataxia, and spasticity. Careful evaluation and consideration is recommended for rare
CMT subtypes or alternative neurologic diagnoses. More
detailed discussion of clinical diagnosis can be found in
several recent publications focusing on this topic.18,19

Genetic diagnosis and counseling
With electrodiagnostic confirmation and classification of
CMT, the decision to pursue genetic testing depends on many
factors. A genetic counselor is an invaluable member of the
multidisciplinary team and can be essential in helping the
patient navigate the ethical, financial, and technical aspects
of genetic testing. Certainly for women in their reproductive
years, the confirmation of a heritable disease can have an
impact on reproductive decisions. Likewise, an asymptomatic but concerned member of a known affected family may
have an interest in genetic testing. However, beyond genetic
confirmation of the diagnosis, the results of genetic testing do
not currently influence subsequent treatment or management
of CMT. Even with the decreasing cost of commercial testing,
it still remains expensive and the patient may encounter problems with insurance coverage for testing. Beyond testing the
most common genes, there are diminishing returns in testing
the increasing number of rare genes unless a specific sign,
symptom, or inheritance pattern allows for a more specific
approach. In a large study of ∼18,000 individuals referred
to commercial testing for CMT, mutations were identified
in ∼18%, leaving the large majority without a clear genetic
etiology.12 Of the patients with identified mutations, 94.9%
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Table 1 Overview of CMT clinical type and genetic subtypes
Type

Pathology/phenotype

Inheritance

% of CMT

Subtype and gene

CMT1

– Myelin abnormalities
– Distal weakness, atrophy,
and sensory loss
– Onset: ∼5–∼20 years
– Motor NCV ,38 m/s

AD

50–80

CMT2

– Axonal degeneration
– Distal weakness and atrophy,
variable sensory involvement
– Complicated and severe
cases described
– Motor NCV .38 m/s
– Onset: variable

AD

10–15

Intermediate
form

– Myelinopathy and axonal
– Motor NCV .25 m/s and
,38 m/s

AD

,4

CMT4

– Demyelinating
– Recessive
– Variable presentations/
phenotypes

AR

Rare

CMTX

– Axonal degeneration with
myelin abnormalities

XL

10–15

CMT1A
CMT1B
CMT1C
CMT1D
CMT1E
CMT1F/2E
CMT2A
CMT2B
CMT2C
CMT2D
CMT2E/1F
CMT2F
CMT2G
CMT2H/2K
CMT2I/2J
CMT2L
CMT2N
CMT2M
CMT2O
CMT2P
CMT2S
CMT2T
CMT2U
DI-CMTA
DI-CMTB
DI-CMTC
DI-CMTD
DI-CMTF
CMT4A
CMT4B1
CMT4B2
CMT4B3
CMT4C
CMT4D
CMT4E
CMT4F
CMT4G
CMT4H
CMT4J
CMT2B1
CMT2B2
CMTX1
CMTX2
CMTX3
CMTX4
CMTX5
CMTX6

PMP22
MPZ
LITAF
EGR2
PMP22
NEFL
MFN2
RAB7A
TRPV4
GARS
NEFL
HSPB1
12q12-q13
GDAP1
MPZ
HSPB8
AARS
DMN
DYNC1H1
LRSAM1
IGHMBP2
DNAJB2
MARS
Unknown
DNM2
YARS
MPZ
GNB4
GDAP1
MTMR2
SBF2
SBF1
SH3TC2
NDRG1
EGR2
PRX
HK1
FGD4
FIG4
LMNA
MED25
GJB1
Xp22.2
Unknown
AIFM1
PRPS1
PDK3

Abbreviations: CMT, Charcot–Marie–Tooth; NCV, nerve conduction velocity; AR, autosomal recessive; AD, autosomal dominant; XL, X-linked.

had mutations in PMP22, MPZ, MFN2, or GJB1. These
numbers are not in agreement with previous studies which
report ∼60% diagnostic rate with genetic testing in confirmed
CMT populations, likely reflecting differences in selection
of patients for genetic testing between CMT/neuromuscular
specialists and non specialists.20
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The advent of next-generation sequencing which can look
for mutations in CMT gene panels, whole exome or genome,
can circumvent complex and potentially costly algorithmic
approaches with parallel sequencing panels of CMT genes,
the whole exome, or even whole genome.12,21 However, the
problem of identifying disease-causing variants not previously
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described in the literature over variants of unknown significance is a significant barrier not unique to CMT. Sequence
databases, such as the NHLBI Exome Sequencing Project
Exome Variant Server (http://evs.gs.washington.edu/EVS/),
can be a helpful aid in discerning common polymorphisms
from rare putative disease-causing variants. An invaluable
resource for referencing disease-causing variants is the
Mutation Database of Inherited Peripheral Neuropathies
(IPNMDB) curated by Vincet Timmerman at the University
of Antwerp (http://www.molgen.ua.ac.be/CMTMutations/
Home/Default.cfm). Beyond its evolving commercial application in identifying known disease-causing mutations, whole
exome and whole genome sequencing remains an important
research tool in the search for new CMT genes, adding to a list
of over 870 mutations across more than 80 genes. However, a
cost conscious sequential approach should be taken by the
clinician, as four genes (PMP22 duplication, GJB1, MPZ,
MFN2) represent .90% of familial CMT cases. A focused
CMT gene panel would reasonably precede whole exome
or genome sequencing in order to optimize costs, time, and
chances of diagnostic genetic achievement.
With such a complicated clinical and genetic heterogeneity, genetic counseling is an essential component of
multidisciplinary care for the CMT patient. Many times,
the genetic counselor directly deals with the emotional and
psychosocial consequences of the loss of independence,
emotional pain, embarrassment, stress around reproduction,
the impact of wearing orthopedic devices, and anxiety over
imminent progressive disability.22 A recent review of genetic
counseling in CMT described the benefits of genetic testing
as: 1) establishing the diagnosis and subtype; 2) confirming
inheritance pattern which may be important in reproductive
counseling; 3) allow for option of prenatal or pre implantation
diagnosis and targeted testing of other family members; 4)
allows for participation in natural history studies and clinical trials which are genotype or CMT subtype focused; 5)
allows for more refined prognostication based on the published literature about the specific mutation; and 6) allows
for diagnosed patients to connect with members of the CMT
community with the same diagnosis.23 The same review
suggested that a standard genetic counseling meeting with
CMT patients should optimally address the aforementioned
items as well as providing support group information or other
community resources, assessment of need for work and home
support service, determination of workplace and insurance
compliance with Americans with Disabilities Act and Genetic
Information Nondiscrimination Act of 2008, assessment of
the psychosocial impact of diagnosis, discussion of possible
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delays and misdiagnosis prior to confirmed CMT diagnosis,
short discussion of symptomatic treatments and encouragement to participate in CMT research studies.

Natural history
CMT is a progressive disease with a wide range of age of
onset and severity. The classically described clinical presentation developed prior to knowledge of its genetic heterogeneity and given our current understanding of genetic prevalence,
likely best describes CMT1. Indeed, the only CMT types with
natural history data are CMT1A and CMTX. The natural
history of CMT2 or more rare CMT subtypes has yet to be
described. What follows is a description of CMT treated as
a generalized disease entity.
Both demyelinating and axonal forms of CMT are
thought of as a length-dependent disease process, which
first affects the distal lower extremities. Its progression is
usually steady and slow, except when a known triggering
or exacerbating factors such as chemotherapy, trauma, or
other stressor such as surgery can precipitate symptoms in
the asymptomatic patient or cause a temporary acceleration
of progression.
Symmetric strength deficits are hallmark features and
are typically seen mostly distal to the knee, but also in the
wrist and hand as the disease progresses into later stages.
Mild-to-moderate proximal musculature weakness and
tremors may also develop in later stages of CMT. Pes cavus,
equinovarus, hammertoes, and claw-hand deformities are
often prevalent in many patients with CMT.24 On examination, loss of light touch, proprioception, vibration, hot/
cold, and pain may be present at diagnosis and with disease
progression. Most patients with CMT do not initially complain of any loss of sensation; however, it is often present
on physical examination. There can be varying degrees of
sensory involvement, but by the time sensory symptoms
reach the knee, they often begin in the hands in a classic
stocking–glove distribution.
Weakness in the anterior lower leg muscles of dorsiflexion may frequently lead to “foot drop” and can have a
strong impact on ambulation and function, and more affected
patients could eventually progress to a non-ambulatory
status confined to a wheelchair.25–27 Subsequent weakness
in the peroneal muscles of eversion in the lower leg could
also allow for excessive inversion and instability at the ankle
joint, making the patient particularly vulnerable to sprains
and falls.28 Also notable, weakness in ankle dorsiflexors may
lead to subsequent tightening of the gastrocnemius, soleus,
and fibrotic changes in the heel cord Achilles tendon, and may
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put the patient at risk for developing an ankle contracture.25,28
Very late-stage or severe impairments may cause contraction
of the unopposed antagonist muscles of the legs, and even
in the hands.25,27

Electrodiagnostic features
As mentioned earlier, classification of CMT is based on
electrodiagnostic findings of either nerve conduction slowing (,38 m/s) in demyelinating forms, or decreased CMAP
amplitudes with preserved conduction speeds in axonal
forms. Occasionally, nerve conduction slowing may fall
into intermediate range between 25 m/s and 45 m/s and is
coined intermediate CMT. Studies of demyelinating CMT
(CMT1A) have shown that while demyelination and slowing
of nerve conduction velocities appear to be the initial pathological insult, secondary axonal loss as measured by CMAP
amplitudes and motor unit number estimation (MUNE)
correlated better with patients’ progressive weakness than
changes in nerve conduction velocity (NCV).29–32 In children
with CMT, electrophysiological changes can be detected as
early as 2 years of age, with abnormally small CMAPs and
progressively worsening NCV until approximately 6 years
of age when it stabilizes.33 Similar loss of axons has been
observed in CMT2, with more proximal involvement and
without changes in NCV.29 In a study, it appears that at least
in CMT1A, the largest amount of axonal loss occurs early
in the disease, with rates of axonal loss when approaching
age-matched controls, but with a lower underlying reserve.30
A 5-year longitudinal study of the natural history of CMT1A
revealed that over 5 years, electrodiagnostic evidence of the
rate of axonal injury and changes in measured grip strength
by dynamometry were not different from age-matched controls, but perceived levels of disability were significantly
worse.34 It has been suggested that progressive disability
stems from worsening muscle weakness and secondary skeletal deformities.30,34 The results of two Italian natural history
studies in CMT1A and CMT2 describe decreases in distal
muscle strength and worsening sensation, but no difference
in QoL, depression, or disability over a 2-year period.35,36

QoL
While CMT patients consistently score lower than healthy
subjects in QoL measures, there is not a direct longitudinal
relation between QoL and physical function or disability.37
The observed paradox between progressive disability and
preserved QoL measured with instruments such as the Short
Form-36 has been discussed, and former methods for assessing both disability and QoL may not be optimal for detecting
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pertinent patient-based outcomes.38 There has been an attempt
to infer disease impact and QoL from clinical examination
findings. Initial studies suggested that tactile sensory tests
related to emotional component of QoL, ability to walk on
toes and heel related to disability and bodily pain.39 Upper
extremity weakness was the most sensitive marker of overall disability as lower extremity strength is impaired in all
CMT patients and likely reaching a ceiling effect early in the
disease. A study has demonstrated lower leg weakness and
cramping correlated with low QoL.40 This same study found
worse physical functioning scores as compared to patients
with epilepsy, diabetes mellitus, angina, and stroke patients
suggesting that the impact of CMT on QoL had previously
been underestimated.
There have been descriptions of the natural history of
CMT1 and CMTX, but prior to the last decade, the relative
rareness of CMT did not allow individual centers to follow
enough patients to sufficiently power rigorous observational
studies (particularly of more rare subtypes) or entertain the
notion of therapeutic trials. Furthermore, there was a lack
of highly developed disease-specific clinical instruments to
describe and quantify disease severity. Over the past decade,
several important developments have co evolved with the
emergence of CMT therapeutic trials that address these
shortcomings. The Inherited Neuropathies Consortium (INC;
https://www.rarediseasesnetwork.org/INC/), part of the Rare
Diseases Clinical Research Network includes ∼17 multinational sites that collect clinical, electrodiagnostic, and genetic
data from CMT patients. The INC will play a pivotal role in
registering CMT patients in sufficient numbers to begin to
power observational studies across multiple clinical sites.
Another key development is an evolving armament
of clinical instruments designed to standardize outcome
measures required for observational studies and therapeutic
trials. The CMT neuropathy score (CMTNS) is a 36-point
composite score that rates the patient’s symptoms, signs, and
neurophysiology, and has been validated as a reproducible
measure of disability in both axonal and demyelinating forms
of CMT.41–43 It was designed to improve standardization of
longitudinal, therapeutic, and multicenter studies. There
were some initial criticisms that the original CMTNS failed
to have translatable value in rehabilitation, and lacked sensitivity related to gross motor and sensory scoring.44–46 Many
of these opinions and observed floor and ceiling effects that
limited the responsiveness of scores to meaningful clinical changes over time were addressed and modified in the
CMTNS version 2.45 The CMTNS version 2 is used to classify
CMT patients into mild (,10, usually walk normally with
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occasional tripping), moderate (11–20, usually walk independently but require ankle–foot orthotic), or severe (.20, usually require walker or wheelchair) disease. It has been used as
primary endpoints in therapeutic trials, and in natural history
studies as discussed in the “Physical therapy and orthoses”
section.13,16,20,34,47–51 The CMT examination score can be used
in patients without electrodiagnostic data, and is simply
the sum of non-neurophysiologic data on the CMTNS.41
The CMT pediatric examination score is another physician determined age-adjusted functional assessment score
designed to assess disability in children.43,52 Many other
outcome measures of impairment and disability have been
implemented and studied in CMT – some as secondary
outcome measures in trials. A thorough cataloging of instruments can be found in the “168th ENMC International
Workshop Report”.46 In response to the observed paradox
between progressive disability and preserved QoL outcomes,
there is a consensus that there remains a need for development of a more sensitive CMT-specific QoL measure.46 The
recently developed mobility-Disability Severity Index is a
patient-reported instrument designed by experienced CMT
practitioners that may offer a complimentary outcome measure based on patient perspectives.53 A separate large-scale
INC registry based study used a survey instrument based
on CMT1A patient input over 20 themes using a six-point
Likert scale and demonstrated novel themes as prioritized
by patients and yielded valuable information on symptom
progression.54 While the use of the aforementioned instruments will continue to evolve, those involved in the optimal
multidisciplinary care of CMT patients will be required to
implement and interpret them effectively. Ideally, the aforementioned instruments and outcome measures will eventually
have generalized utility for the neurologist, genetic counselor,
physical and occupational therapist, and physiatrist caring
for the CMT patient.
A large survey of over 400 CMT patients in the INC
Rare Disease Clinical Research Network Contact registry
identified patient-reported foot and ankle weakness, balance,
mobility and hand/finger weakness as the most prevalent
themes that affected QoL, but also demonstrated that fatigue,
pain, and body image are likely under-recognized influences
on perceived QoL.54 Besides function limiting themes such
as poor balance and mobility limitations, individual symptoms reported as most impactful include difficulty/inability
to run, trouble when getting around slippery surfaces, and
trouble walking distances and on rough ground. The impact
of symptoms appear to have the largest effect over the first
10 years following diagnosis, with a less rapid increase
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over the ensuing years, so that disease progression is better predicted by duration than by age. While this may be
due to survivor bias and improved coping strategies, it also
argues for more aggressive multidisciplinary supportive
care over the first decade after diagnosis. The results of
such studies demonstrate the power of large-scale registry
and patient-based reporting to identify diverse sets of issues
important to patients’ QoL that fall outside the realm of a
single discipline.

Clinical surveillance of
comorbidities, complications, and
medications to avoid
Beyond monitoring for and treating physical impairments,
there is evidence for less well recognized comorbidities and
complications in CMT. As mentioned earlier, these underappreciated problems likely negatively impact QoL, but in many
cases may be treatable.
Prospective studies regarding the location, severity
duration, triggering factors, and impact on QoL of cramps
in CMT demonstrated that hand, finger, thigh, and trunk
muscle cramps are a stable symptom that clearly impacted
QoL.40,54 In pediatric CMT1A, muscle cramps, tremor, and
distal weakness were shown to be associated with lower
QoL measures.52 Adoption of formerly off-label drugs for
CMT-related symptoms, such a mexiletine for cramping,
will likely lead to new indications and improved QoL for
CMT patients.
Respiratory and sleep disorders observed in CMT include
restrictive pulmonary impairment, obstructive sleep apnea,
restless legs syndrome, and vocal cord dysfunction/laryngeal
neuropathy.55 In a large German web-based survey study
of over 200 CMT patients, CMT patients reported more
fatigue, daytime sleepiness, and poorer sleep quality as well
as a three fold increase in restless leg syndrome.56 A number
of small reports describe symptoms of dyspnea, dysphagia,
and obstructive sleep apnea, laryngoscopic evaluation of the
upper airway, as well as treatment with continuous or bi-level
positive airway pressure.55,57–62 While there is not enough evidence to make recommendations regarding clinical screening
for sleep and respiratory disorders, longitudinal care should
optimally address these potential comorbidities.
Worsening of CMT symptoms during pregnancy has
been reported.63 This observation has led to investigations
into progesterone antagonism as a possible therapy in CMT,
which is discussed in more detail in the “Therapeutics” section. CMT was shown to increase the risk for complications
during delivery, specifically abnormal birth presentation
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and post partum bleed, and with higher rates of emergency
interventions during delivery.64 While there are no evidencebased recommendations regarding obstetric anesthesia, it is
thought that regional anesthesia is an appropriate alternative to general anesthesia in CMT patients.65 CMT should
be considered an independent risk factor for complication
during pregnancy and delivery and warrants involvement of
a multidisciplinary team.
Many medications are known to have the potential to
worsen CMT. The prototypical neurotoxic offenders are chemotherapies such as taxols and the vinca alkaloids that target
microtubules.66 These microtubule depolymerizing agents
are thought to interrupt axonal transport along microtubules
and worsen preexisting neuropathy or even precipitate new
neuropathy. This observation has been used to bolster the idea
that axonal transport explains the length-dependent progression of CMT.67 Chemotherapies are not the only offending
agents, and a list of potentially exacerbating medications
organized by certainty of risk is maintained and updated by
the CMT Association (http://www.cmtausa.org/).68

Therapeutics
While the last decade has seen the first CMT clinical trials,
there are no clinical data supporting use of medications, and
the management of CMT remains supportive. The mainstay
of supportive care is physical therapy as discussed in the next
sections. While many drugs are under examination, there is
only one ongoing clinical trial (PLEO-CMT, ClinicalTrials.
gov identifier NCT02579759) in humans of combination of
baclofen, naltrexone, and sorbitol (PXT3003).69–71
Clinical trials have been largely driven by observation in
animal models of CMT1A. The bulk of clinical trial efforts
centered around the use of ascorbic acid, a known promoter
of myelination which has been shown to reduce expression
levels of PMP22, improve locomotor function, and prolong
life in CMT1A rodent models.72 This led to a randomized
double-blind, placebo controlled trial of high dose ascorbic
acid (30 mg/kg/day) in children, with a primary endpoint
of median nerve motor conduction at 1 year, and secondary
outcomes of foot and hand strength, motor function, walking
ability, and QoL.73 A total of 80 children completed the trial,
and a non significant increase in median nerve conduction
motor velocity was observed, with no difference in secondary
outcomes. A similar study in adult CMT1A patients (N=179)
randomized to 1 g or 3 g of ascorbic acid a day or placebo
used the CMTNS at 1 year as the primary outcome and
included secondary outcome measures of muscle strength,
gait velocity, disability, fatigue, pain, and cramping scales,
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as well as the global impression severity score.74 No significant differences in primary or secondary outcomes were
observed. A third randomized, high dose ascorbic acid (1 g
twice daily), double-blind study in young adults (age ,25
years, N=11) using a primary outcome of median NCV and
neurophysiological secondary outcome measures, failed to
show any significant effect.75 In these studies, the high doses
of ascorbic acid treatment were well tolerated. Given the non
significant results and the slow progression of the disease, it
was thought that a 1-year follow-up may not have been long
enough to capture the effect of ascorbic acid. Two subsequent
2-year trials of low and high doses of ascorbic acid (1.5 g/
day, N=277 and 4 g/day, N=110) in adults failed to show
significant differences in similar outcome measures.76,77
A number of smaller non randomized non-blinded studies
have shown potential promise in agents such as coenzyme Q10,
linoleic acid, and potassium channel blockers, but rigorous
clinical data are lacking.78,79 The observation that in a small
cohort of female CMT1 patients (N=21, 45 gestations), 38%
experienced a worsening of CMT symptoms during pregnancy
suggests a possible link with pregnancy-associated hormonal
changes.63 Transgenic rat models of CMT1A implicated progesterone receptors on Schwann cells as mediating this link to
progesterone during pregnancy. Administering exogenous progesterone to CMT1A drove the CMT phenotype, and progesterone antagonists reduced PMP22 expression and improved
CMT phenotypes.80 Further studies demonstrated that antiprogesterone therapy improved motor strength and axonal
loss, but did not change myelin thickness or nerve conduction
velocities, effectively uncoupling axonal loss from demyelination.81 Formal clinical trials of anti-progesterone therapy in
CMT have yet to be reported, largely due to the significant
side effect profile of current anti-progesterones. Additional
investigations into coenzyme Q10, curcumin, NTF3, and other
study drugs are at various stages of development.46,82,83

Physical therapy and orthoses
While there are distinct genetic causes, neurophysiological
properties, and underlying disease mechanisms, the physical deficits of CMT are uniform enough to approximate and
discuss it as a singular entity. Future studies of CMT subtypes
may reveal important differences in response to physical
therapies, orthotics, and more specific recommendations
regarding exercise. Likewise, data collection from large
national patient registries may help investigators retrospectively analyze which durable medical equipment and adaptive
devices are best suited for improving function in patients with
CMT along the natural history of the disease.
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Important aspects of physical therapy and rehabilitation
for patients with CMT may involve gait training, therapeutic exercise, stretching, balance and postural stabilization,
fall risk prevention strategies, aquatic therapy, energy
conservation techniques, serial casting/night splinting,
patient education, training on appropriate assistive devices,
and prevention of secondary impairments.25–28,84–91 Likewise,
time should be taken to educate the patient on lifestyle modifications and energy conservation techniques along with the
progression of the disease and impairments in body structures
and function.89
Protection of joint range of motion (ROM) to avoid the
possibility of contractures and maximize functional use of all
extremities should be stressed in the management of CMT.25
Night splinting, however, according to the most current
evidence does not appear to be the most effective means for
long-term improvements in ankle ROM.28,89 Occupational
therapy and/or certified hand therapists should be incorporated with managing both early- and late-stage impairments
in patients with limited wrist and hand strength and ROM,
as well as children with hand dysfunction.92 Weakness, pain,
dysmetria, difficulty with handwriting, and discoordination,
among several other impairments, may greatly affect upper
limb function in the patient with CMT as a child or adult and
they may benefit greatly from occupational, vocational, and
hand therapies to improve compensatory strategies, utilize
assistive technology, improve age-appropriate function, and
accommodate for their impairment.92
Patients with CMT frequently stumble, trip, or fall due
to weakness and sensory deficits distal to the knee joint,
and often display compensatory strategies in proximal hip
and pelvic muscles which are recruited to modify gait patterns.24,90 It has been shown that various types of properly
fitted ankle–foot orthoses (AFO) may significantly reduce
the need for proximal compensations and can improve lower
extremity control during ambulation. Similarly, Dufek et al
demonstrated that patients with CMT display increased gait
speed when using AFO compared to no bracing.93 Anterior
elastic AFO appear to reduce the energy cost of ambulation
in CMT.94 After fitting of AFO, patients should receive proper
gait training to assist with adapting and normalizing their biomechanics during locomotion, maximizing their functional
ambulation potential, and avoiding further compensatory
movements for energy efficiency.84,93 Likewise, patients
should be educated on prevention of skin breakdown while
wearing orthoses and braces.
Orthoses aimed at offering structural support to focal,
and/or global ankle and foot weakness may range from simple
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shoe inserts to complete AFO bracing, may be plastic or elastic in nature, and may be fabricated from durable plastics to
custom carbon-fiber composites.24,28,84–91,93,95–97A recent study
by Wegener et al demonstrated that in a small population
of adult patients with CMT sensorimotor in-shoe orthoses
proved to be more comfortable, better cushioned, and had a
positive effect on overall lower extremity kinematics during
ambulation.98 A comprehensive evaluation of ROM, sensation, reflexes, strength, and balance should be performed
when deciding which AFO device is best suited for each
individual patient. Despite their effectiveness in improving
gait, foot pain, and mild balance impairments in patients with
CMT, adherence to AFO-wearing schedules remains poor.96
Poor compliance with wearing AFO in CMT has been well
documented across various age ranges in recent studies, often
for comfort and cosmetic reasons.99,100
Surgical correction may be required in cases of chronic
ankle sprains, shoe-wearing difficulty, and pain not helped
by orthoses.24 Surgical goals are to realign joints, correct
boney deformities, and to balance muscles, and require a
high degree of individualization. Evaluation of foot alignment, strength, and weight-bearing radiographs are used to
guide the surgeon’s strategy.
Surgery for foot deformities is common in CMT patients
yet a systematic review is lacking. Some recent reports have
suggested early minimally invasive procedures including
plantar fasciotomy, Achilles tendon lengthening, transfer of
the peroneus longus to the fifth metatarsal, tendon transfer, and
hammertoe correction may preserve the utility of braces and
reduce the need for further surgery.101,102 The aim of an early
minimally invasive approach is to decrease the forces and intrinsic/extrinsic muscle imbalances that underlie progressive foot
deformity. Later stage reconstructive surgery usually includes
staged procedures of tendon lengthening and or transfer, osteotomy, and arthrodesis.101,102 In the more severe forms of CMT,
orthopedic correction of spinal deformity and hip dysplasia may
be required. For a more detailed review of surgical and orthopedic issues in CMT, the reader is referred to Yagerman et al.24
Overwork weakness is another common finding throughout neuromuscular disorders that may require adaptation
and utilization of energy conservation techniques. 89,90
Although there is conflicting evidence on the concept of
overwork weakness, recent findings of bilateral hand and leg
strength suggests it may not manifest in CMT as previously
thought, and this phenomenon may be more individualized
to each patient case.90 Therefore, low-to-moderate-intensity
exercise should be regularly encouraged as it should have
overall systemic health benefits.25,26,90,103 Interval training,
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by its very nature incorporating periods of rest and exercise,
appears to display marked improvements in cardiorespiratory, strength, and functional capacities, and likely slows or
reverses the deconditioning process often seen in patients
with CMT.26,104,105
Low-intensity exercise appears to be more beneficial
for patients with neuromuscular disease when compared to
high-resistance or high-intensity exercise.25Aquatic therapy,
in theory, may be of great benefit due to its unweighting
properties and dynamic resistance during underwater movements, but more evidence and studies are needed in this area.
Likewise, a home-based resistance training exercise program
focused on activities of daily living (ADL)-specific exercises
improved strength and ADL equally in both adult males and
females with CMT.105 Stretching should play an important
role in the maintenance of patients with CMT to protect
joint ROM in order to optimize the functional use of their
extremities as their weakness persists. Occupational therapy
should also be considered for those patients needing adaptive
equipment and further training to improve independence with
self-care and ADL.
Patients with CMT will commonly present with increasing sensorimotor loss distal to the knee that will greatly
benefit from AFO and the ongoing care of an orthotist. Also,
interval training, and low- to-moderate-intensity aerobic and
resistance exercise can be therapeutic and is not likely to
negatively impact a patient’s function. Energy conservation
techniques and lifestyle modifications are key educational
concepts for the patient with CMT, albeit, are very patientspecific. Often patients with CMT will develop weakness and
limited ROM in their wrists and hands in later stages that
can be addressed by skilled hand therapists, and occupational
and physical therapy modalities. Patients with CMT should
invariably be part of an ongoing multidisciplinary plan of
care in regards to their functional impairments; including
but not limited to: physical and occupational therapist, physiatrist, orthotist, neurologist, and hand therapist, in order to
manage each impairment to its fullest and achieve maximum
functional benefit. More high-quality trials and evidence are
needed to draw sound conclusions on the benefits of aquatic
therapy, specific therapeutic modalities, exercising, stretching protocols, balance training, night splinting/serial casting,
and assistive technology devices in the management of CMT
disease. Likewise, the emergence of large-scale patient registries, such as the INC and well-defined natural histories,
will enable researchers to investigate how therapies might
be optimally tailored to the needs of specific CMT clinical
and genetic subtypes.
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The need for multidisciplinary
care in CMT
In summary, while the medical diagnosis of CMT is traditionally made by the neurological specialist, the optimal
management of CMT patients includes genetic counselors,
physical and occupational therapists, physiatrists, orthotists,
social workers, mental health providers, and community
resources (Table 2). Continued genetic discoveries continue
to add to the complexity of CMT, and knowledge of each
CMT subtype will likely shape the way each member of
the multidisciplinary team approaches the disease. Several important trends in CMT research discussed earlier,
including the development of large multicenter patient registries, standardized clinical instruments to assess disease
progression and disability, and increasing recognition of
patient-reported factors will likely make significant improvements to CMT patients’ QoL. These developments have
and will continue to identify novel targetable and treatable

Table 2 Multidisciplinary members and roles in the diagnosis and
management of CMT
Neurologist

Genetic counselor and
social worker

Physical and occupational
therapist/physiatrist

Psychologist/psychiatrist

Orthopedic surgeon

• Evaluation and diagnosis
• Prognostication
• Consideration for research studies
• Referrals to genetic counselors, PT/OT,
mental health
• Longitudinal care and reevaluation
• Counseling on medications to avoid
• Surveillance of comorbidities
• Lifestyle modifications to limit disability
• Guidance in clinical- and research-based
genetic testing
• Ensuring ADA and GINA compliance
• Discussion of family testing
• Reproductive counseling
• Referral to CMT Association and other
community organization
• Evaluation of upper and lower
extremity disability
• Prescription for ankle–foot orthotics
• Recommendations for therapeutic
exercise, stretching, balance and
postural stabilization, fall risk
prevention strategies
• Recommendation on exercise, lifestyle
modification to limit disability
• Evaluation and treatment of anxiety,
depression, and other psychosocial
impact of diagnosis, such as body image
• Evaluation and treatment of severe
foot, ankle, hip, and spine deformities

Abbreviations: CMT, Charcot–Marie–Tooth; ADA, Americans with Disabilities
Act; GINA, Genetic Information Nondiscrimination Act of 2008; PT, physical
therapist; OT, occupational therapist.
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Occupational and
hand therapist
Physiatrist/
physical therapy

Lifestyle
modifications,
assistive device
training
Gait training, therapeutic
exercise, stretching,
balance and postural
stabilization, fall risk
prevention strategies

Severe
deformity and
orthotic failure

Evaluation and
prescription of
orthotics

Genetic
counselor

Neurologist
AD
Suspicion of CMT
by history and
neurologic exam

AR
Demyelinating
CMT1

1) PMP22 dup, GJB1
2) MPZ, PMP22
3) GDAP1, EGR2, LITAF
1) SH3TC2, PRX
2) GDAP1

X-linked
1) GJB1/CNX32

More detailed
algorithms using
NCV and age of
onset

a

NCS/EMG

Longitudinal
follow-up

Sporadic
1) PMP22 dup, GJB1
2) MPZ, PMP22
3) GDAP1, PRX, EGR2, LITAF

AD
AR

1) MFN2
2) MPZ
3) GARS, RAB7, NEFL, HSPB1
1) GDAP

Axonal/CMT2
X-linked

1) GJB1/CNX32

Orthotist
Orthopedic
surgeon

Mental health
– Evaluate and treat
psychosocial aspects of
diagnosis

Research resources

Sporadic
1) MFN2, GJB1/CNX32
2) MPZ
3) GARS, RAB7, NEFL, HSPB1,
GDAP1

– Inherited neuropathies consortium
– Natural history studies
– Research-based genetic testing
– Therapeutic/clinical trials

Genetic results

Community resources
– CMT Association
– MDA/MDA clinics
– Hereditary neuropathy foundation

Social worker

Figure 1 Flow of multidisciplinary care in diagnosis and management of CMT.
Notes: aA simplification of published strategies of genetic testing in CMT as described by Saporta et al106 and Miller et al.107 The order of genetic testing (1, 2, 3) is guided by
electrodiagnostic findings and inheritance pattern. Please refer to Saporta et al106 and Miller et al107 for more detailed recommendations on strategies of cost conscious sequential
genetic testing.
Abbreviations: CMT, Charcot–Marie–Tooth; dup, duplication; NCS, nerve conduction studies; EMG, electromyography; MDA, Muscular Dystrophy Association; AD,
autosomal dominant; AR, autosomal recessive.

deficits, symptoms, and disabilities that will likely require a
collaborative multidisciplinary approach (Figure 1). Many of
these multidisciplinary services are coordinated and offered
by muscular dystrophy clinics or established CMT-based
clinics (Charcot–Marie–Tooth Disease Clinic at the University of Iowa (https://www.uihealthcare.org/charcot-marietooth-disease/). Ongoing CMT research struggles to identify
novel therapeutics to slow or stop disease progression, but
the evolving strategies in long-term multidisciplinary care of
CMT patients is critical in maintaining QoL and functionality with disease progression.
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